ES2179862T3 - Utilizacion de rapamicina para el tratamiento de la anemia. - Google Patents
Utilizacion de rapamicina para el tratamiento de la anemia.Info
- Publication number
- ES2179862T3 ES2179862T3 ES95308503T ES95308503T ES2179862T3 ES 2179862 T3 ES2179862 T3 ES 2179862T3 ES 95308503 T ES95308503 T ES 95308503T ES 95308503 T ES95308503 T ES 95308503T ES 2179862 T3 ES2179862 T3 ES 2179862T3
- Authority
- ES
- Spain
- Prior art keywords
- rapamycin
- anemia
- treatment
- mammal
- intrabronchially
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
EN ESTA INVENCION SE PRESENTA UN METODO PARA EL TRATAMIENTO DE LA ANEMIA INMUNORRELACIONADA DE UN MAMIFERO QUE CONSISTE EN ADMINISTRAR RAPAMICINA A DICHO MAMIFERO POR VIA ORAL, PARENTERAL, INTRAVASCULAR, INTRANASAL, INTRABROQUIAL, TRANSDERMICA, RECTAL.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/354,977 US5561138A (en) | 1994-12-13 | 1994-12-13 | Method of treating anemia |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2179862T3 true ES2179862T3 (es) | 2003-02-01 |
Family
ID=23395715
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES95308503T Expired - Lifetime ES2179862T3 (es) | 1994-12-13 | 1995-11-27 | Utilizacion de rapamicina para el tratamiento de la anemia. |
Country Status (12)
Country | Link |
---|---|
US (1) | US5561138A (es) |
EP (1) | EP0716857B1 (es) |
JP (1) | JPH08208661A (es) |
KR (1) | KR100423825B1 (es) |
AT (1) | ATE215822T1 (es) |
CA (1) | CA2164921A1 (es) |
DE (1) | DE69526311T2 (es) |
DK (1) | DK0716857T3 (es) |
ES (1) | ES2179862T3 (es) |
HK (1) | HK1010345A1 (es) |
MX (1) | MX9505187A (es) |
PT (1) | PT716857E (es) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1289815B1 (it) * | 1996-12-30 | 1998-10-16 | Sorin Biomedica Cardio Spa | Stent per angioplastica e relativo procedimento di produzione |
US6667300B2 (en) | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
US6670355B2 (en) | 2000-06-16 | 2003-12-30 | Wyeth | Method of treating cardiovascular disease |
DE60136200D1 (de) | 2000-09-19 | 2008-11-27 | Wyeth Corp | Wasserlösliche rapamycin-ester |
US6399625B1 (en) | 2000-09-27 | 2002-06-04 | Wyeth | 1-oxorapamycins |
US6440991B1 (en) | 2000-10-02 | 2002-08-27 | Wyeth | Ethers of 7-desmethlrapamycin |
US6399626B1 (en) | 2000-10-02 | 2002-06-04 | Wyeth | Hydroxyesters of 7-desmethylrapamycin |
TWI286074B (en) | 2000-11-15 | 2007-09-01 | Wyeth Corp | Pharmaceutical composition containing CCI-779 as an antineoplastic agent |
TWI296196B (en) * | 2001-04-06 | 2008-05-01 | Wyeth Corp | Antineoplastic combinations |
TWI233359B (en) * | 2001-04-06 | 2005-06-01 | Wyeth Corp | Pharmaceutical composition for treating neoplasm |
ZA200603888B (en) * | 2001-06-01 | 2007-05-30 | Wyeth Corp | Antineoplastic combinations |
UA77200C2 (en) | 2001-08-07 | 2006-11-15 | Wyeth Corp | Antineoplastic combination of cci-779 and bkb-569 |
DE60206512T2 (de) | 2001-08-22 | 2006-06-22 | Wyeth | Rapamycin 29-enole |
US6680330B2 (en) | 2001-08-22 | 2004-01-20 | Wyeth | Rapamycin dialdehydes |
CA2493878C (en) | 2002-07-30 | 2013-07-23 | Wyeth | Parenteral formulations containing a rapamycin hydroxyester |
MXPA05002828A (es) * | 2002-09-17 | 2005-05-27 | Wyeth Corp | Formulaciones orales. |
AR042938A1 (es) * | 2003-02-06 | 2005-07-06 | Wyeth Corp | Uso del cci-779 en el tratamiento de la fibrosis hepatica |
UA83484C2 (uk) * | 2003-03-05 | 2008-07-25 | Уайт | Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція |
US20040258662A1 (en) * | 2003-04-22 | 2004-12-23 | Wyeth | Antineoplastic agents |
CN101031569B (zh) | 2004-05-13 | 2011-06-22 | 艾科斯有限公司 | 作为人磷脂酰肌醇3-激酶δ抑制剂的喹唑啉酮 |
JP2008500338A (ja) * | 2004-05-25 | 2008-01-10 | イコス・コーポレイション | 造血細胞の異常増殖を治療及び/又は予防する方法 |
AU2005294382A1 (en) * | 2004-10-04 | 2006-04-20 | Qlt Usa, Inc. | Ocular delivery of polymeric delivery formulations |
US8313763B2 (en) * | 2004-10-04 | 2012-11-20 | Tolmar Therapeutics, Inc. | Sustained delivery formulations of rapamycin compounds |
CN102579467A (zh) | 2005-11-14 | 2012-07-18 | 阿里亚德医药股份有限公司 | 雷帕霉素衍生物在治疗癌症中的用途 |
RU2010104916A (ru) * | 2006-08-16 | 2011-08-20 | Михаил В. Благосклонный (US) | Способ профилактики и лечения возрастных заболеваний |
CN104906087A (zh) | 2006-09-13 | 2015-09-16 | 万能医药公司 | 大环内酯化合物及它们的使用方法 |
EP2352459A4 (en) * | 2008-10-03 | 2013-09-25 | Elixir Medical Corp | MACROCYCLIC LACTONE COMPOUNDS AND METHODS OF USE |
CN102292078A (zh) | 2008-11-11 | 2011-12-21 | 得克萨斯大学体系董事会 | 哺乳动物雷帕霉素靶蛋白的抑制 |
US9492449B2 (en) | 2008-11-13 | 2016-11-15 | Gilead Calistoga Llc | Therapies for hematologic malignancies |
AU2009313878B2 (en) | 2008-11-13 | 2016-01-07 | Gilead Calistoga Llc | Therapies for hematologic malignancies |
BRPI1012333A2 (pt) | 2009-03-24 | 2016-03-29 | Gilead Calistoga Llc | atropisômeros de derivados de 2-purinil-3-tolil-quinazolinonas e métodos de uso |
KR20130128018A (ko) | 2009-04-10 | 2013-11-25 | 하이얀 치 | 새로운 노화 방지 물질 및 그 확인 방법 |
US8546409B2 (en) | 2009-04-20 | 2013-10-01 | Gilead Calistoga Llc | Methods of treatment for solid tumors |
CN102647987A (zh) | 2009-07-21 | 2012-08-22 | 吉里德卡利斯托加公司 | 使用pi3k抑制剂治疗肝脏障碍 |
US9364507B2 (en) * | 2009-08-11 | 2016-06-14 | Imagilin Technology, Llc | Probiotic enhancement of steroid and immune suppressor activity in mammals with chronic diseases |
US9283211B1 (en) | 2009-11-11 | 2016-03-15 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
BR112014021935A2 (pt) | 2012-03-05 | 2019-09-24 | Gilead Calistoga Llc | formas polimórficas de (s)-2(l-(9h-purin-6-ilamino)propil)-5-fluoro-3-fenilquinazolina-4(3h)ona |
WO2014059295A1 (en) | 2012-10-12 | 2014-04-17 | The Board Of Regents Of The University Of Texas System | Use of mtor inhibitors to treat vascular cognitive impairment |
WO2014160328A1 (en) | 2013-03-13 | 2014-10-02 | The Board Of Regents Of The University Of Texas System | Mtor inhibitors for prevention of intestinal polyp growth |
NZ720867A (en) | 2013-12-20 | 2018-01-26 | Gilead Calistoga Llc | Process methods for phosphatidylinositol 3-kinase inhibitors |
WO2015095605A1 (en) | 2013-12-20 | 2015-06-25 | Gilead Calistoga Llc | Polymorphic forms of a hydrochloride salt of (s) -2-(9h-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3h) -one |
CA3206208A1 (en) | 2013-12-31 | 2015-07-09 | Rapamycin Holdings, Llc | Oral rapamycin nanoparticle preparations and use |
US9700544B2 (en) | 2013-12-31 | 2017-07-11 | Neal K Vail | Oral rapamycin nanoparticle preparations |
BR112016028642A2 (pt) | 2014-06-13 | 2017-08-22 | Gilead Sciences Inc | composto, composição farmacêutica, método de tratamento de uma doença ou condição, método de inibição da atividade de um polipeptídeo de fosfatidilinositol 3-quinase, método de inibição de reações imunes ou crescimento excessivo ou destrutivo ou de proliferação de células cancerosas, kit, e, uso de um composto, de um sal, de um isômero ou de uma mistura farmaceuticamente aceitável do mesmo. |
IL298156A (en) * | 2020-05-15 | 2023-01-01 | Celgene Corp | Methods and preparations for the treatment of anemia using actriib ligand traps and mtor inhibitors |
CN116459248B (zh) * | 2023-04-27 | 2024-02-13 | 中国人民解放军陆军军医大学第二附属医院 | 雷帕霉素在制备治疗肿瘤相关性贫血的药物中的应用和药物 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA737247B (en) * | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
US3993749A (en) * | 1974-04-12 | 1976-11-23 | Ayerst Mckenna And Harrison Ltd. | Rapamycin and process of preparation |
US5206018A (en) * | 1978-11-03 | 1993-04-27 | Ayerst, Mckenna & Harrison, Inc. | Use of rapamycin in treatment of tumors |
US4885171A (en) * | 1978-11-03 | 1989-12-05 | American Home Products Corporation | Use of rapamycin in treatment of certain tumors |
US4401653A (en) * | 1981-03-09 | 1983-08-30 | Ayerst, Mckenna & Harrison Inc. | Combination of rapamycin and picibanil for the treatment of tumors |
US5100899A (en) * | 1989-06-06 | 1992-03-31 | Roy Calne | Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof |
KR100215167B1 (ko) * | 1990-08-10 | 1999-08-16 | 위샤르트 아이 시 | 면역 억제 조성물 |
US5080899A (en) * | 1991-02-22 | 1992-01-14 | American Home Products Corporation | Method of treating pulmonary inflammation |
US5078999A (en) * | 1991-02-22 | 1992-01-07 | American Home Products Corporation | Method of treating systemic lupus erythematosus |
US5321009A (en) * | 1991-04-03 | 1994-06-14 | American Home Products Corporation | Method of treating diabetes |
IL101353A0 (en) * | 1991-04-03 | 1992-11-15 | American Home Prod | Pharmaceutical compositions for treating diabetes |
US5091389A (en) * | 1991-04-23 | 1992-02-25 | Merck & Co., Inc. | Lipophilic macrolide useful as an immunosuppressant |
ATE135583T1 (de) | 1991-06-18 | 1996-04-15 | American Home Prod | Verwendung von rapamycin zur behandlung von t- zellen lymphom/leukämie bei erwachsenen |
ZA924953B (en) | 1991-07-25 | 1993-04-28 | Univ Louisville Res Found | Method of treating ocular inflammation |
US5286731A (en) * | 1991-09-17 | 1994-02-15 | American Home Products Corporation | Method of treating immunoinflammatory bowel disease |
US5286730A (en) * | 1991-09-17 | 1994-02-15 | American Home Products Corporation | Method of treating immunoinflammatory disease |
US5288711A (en) * | 1992-04-28 | 1994-02-22 | American Home Products Corporation | Method of treating hyperproliferative vascular disease |
GB9221220D0 (en) * | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
GB9302567D0 (en) * | 1993-02-10 | 1993-03-24 | Smithkline Beecham Plc | Novel compound |
CH686761A5 (de) * | 1993-05-27 | 1996-06-28 | Sandoz Ag | Galenische Formulierungen. |
-
1994
- 1994-12-13 US US08/354,977 patent/US5561138A/en not_active Expired - Lifetime
-
1995
- 1995-11-27 AT AT95308503T patent/ATE215822T1/de not_active IP Right Cessation
- 1995-11-27 ES ES95308503T patent/ES2179862T3/es not_active Expired - Lifetime
- 1995-11-27 DK DK95308503T patent/DK0716857T3/da active
- 1995-11-27 DE DE69526311T patent/DE69526311T2/de not_active Expired - Fee Related
- 1995-11-27 PT PT95308503T patent/PT716857E/pt unknown
- 1995-11-27 EP EP95308503A patent/EP0716857B1/en not_active Expired - Lifetime
- 1995-12-11 CA CA002164921A patent/CA2164921A1/en not_active Abandoned
- 1995-12-11 MX MX9505187A patent/MX9505187A/es unknown
- 1995-12-12 JP JP7323042A patent/JPH08208661A/ja active Pending
- 1995-12-12 KR KR1019950048544A patent/KR100423825B1/ko not_active IP Right Cessation
-
1998
- 1998-10-20 HK HK98111349A patent/HK1010345A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CA2164921A1 (en) | 1996-06-14 |
DE69526311T2 (de) | 2002-11-28 |
ATE215822T1 (de) | 2002-04-15 |
HK1010345A1 (en) | 1999-06-17 |
DK0716857T3 (da) | 2002-08-05 |
KR960021019A (ko) | 1996-07-18 |
KR100423825B1 (ko) | 2004-06-26 |
EP0716857A1 (en) | 1996-06-19 |
MX9505187A (es) | 1997-04-30 |
DE69526311D1 (de) | 2002-05-16 |
EP0716857B1 (en) | 2002-04-10 |
JPH08208661A (ja) | 1996-08-13 |
PT716857E (pt) | 2002-08-30 |
US5561138A (en) | 1996-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2179862T3 (es) | Utilizacion de rapamicina para el tratamiento de la anemia. | |
KR930703001A (ko) | 전신 홍반성낭창의 치료방법 | |
NL300180I2 (nl) | Toepasen van toxmoxetine voor het behandelen van de concentratiestoornis/hyperactiviteit aandoening. | |
PT1143967E (pt) | Utilizacao de derivados anticonvulsivos para o tratamento de cefaleias em salvas | |
TR199902033T2 (xx) | Diyabet i�in s�lfonilura-glitazon sinerjik kombinasyonlar�. | |
PT1039887E (pt) | Metodos para o tratamento de neuro e nefro disturbios e de toxicidades terapeuticas usando compostos de aminotiol | |
FR2717546B1 (fr) | Tendeur de courroie. | |
ES2059121T3 (es) | Uso de agentes sensibilizantes de insulina para tratar la hipertension. | |
MX9205549A (es) | Metodo para el tratamiento de vih. | |
BR0214020A (pt) | Método para tratar fibrose cìstica | |
MX9205628A (es) | Operaciones de oxidacion mejoradas para el tratamiento de desperdicios. | |
EA199800816A1 (ru) | Способы лечения и профилактики интерстициального цистита | |
DE29906545U1 (de) | Maschine zum Feinbearbeiten der Zahnflanken von verzahnten Werkstücken | |
DE69303305T2 (de) | Mittel zur Behandlung chronischer Ermüdungserscheinungen | |
DK0571457T3 (da) | Iloprost med virkning overfor cerebral malaria. | |
GB2310626B (en) | Device for the finishing,particularly of crankshafts or camshafts | |
DE60129552D1 (de) | E-selectin zur behandlung oder vorbeugung von schlaganfall | |
DE29821826U1 (de) | Riemen für Gefäßbehandlungsmaschinen | |
BR9710901A (pt) | M-todo para o tratamento da doen-a bipolar | |
DE60126766D1 (de) | Zuführvorrichtung zum Zuführen von Stangen und Entfernen von Abfallstücken | |
ES1013369Y (es) | Maquina elaboradora para el tratamiento de superficies de piezas de trabajo. | |
PT690712E (pt) | Taxanos possuindo uma cadeia lateral substituida com piridilo | |
ES1030953Y (es) | Maquina para el procesado de piezas de jamon. | |
FR2805755B1 (fr) | Machine de traitement de skis a entrainement lateral | |
DE59710787D1 (de) | Vorrichtung zum massfinishen von kurbelwellen oder dergleichen werkstücken |